[Meningitis]
serum sickness, 137
serum tests.SeeSerum
symptoms and signs of, 135
viruses and, 135
Meningococcal cellulitis, 299
Meningococcal vaccine, 355
Meningococcemia, 70
Meningoencephalitis, 135
in SOT recipients, 400
Meningovascular syphilis, 158
Meropenem, 544
Methicillin-resistantStaphylococcus aureus
(MRSA), 170, 173, 345, 530
ABE, 208, 210–214
combination therapy for, 213
diagnostic clinical pathway, 212
CA-MRSA.SeeCommunity-acquired
methicillin-resistantStaphylococcus aureus
(CA-MRSA)
CAP and, 170, 173
control measures for, in ICUs, 111
CVC infections and, 208
antibiotic therapy of, 213–214
classification of, 212
endocarditis and, 218
gastrointestinal carriage of, 110
HA-MRSA.SeeHospital-acquired
methicillin-resistantStaphylococcus
aureus(HA-MRSA)
HAP and, 180
prevention and control of, in ICUs
contact precautions, 108
cost effectiveness, 110, 112
decolonization of patients.See
Decolonization
decontamination of environment, 108
hand hygiene, 108–109
screening patients for colonization, 108
types of infections caused by, 104
VAP, 191
linezolid therapy for, 192–193
Methicillin-sensitiveStaphylococcus aureus
(MSSA), 530
ABE, 208, 210–214
combination therapy for, 213
diagnostic clinical pathway, 212
CAP and, 170
CVC infections and, 208
antibiotic therapy of, 213–214
endocarditis and, 218
HAP and VAP and, 170
Methicillin-susceptibleStaphylococcus aureus
(MSSA), 103
Methotrexate, 377
Metronidazole, 400, 538, 551
for CDI treatment, 281
MI.SeeMyocardial infarction (MI)
MIC.SeeMinimum inhibitory concentration
(MIC)
Microaspiration, HAP and, 179
Microbial surface components recognizing
adhesive matrix molecules
(MSCRAMMS), 218
ofS. viridans, 220
Microbial virulence, severe CAP and, 164
Micrococcusspp.
skin and soft tissue infections and, 295
MICU.SeeMedical intensive care unit (MICU)
Miliary tuberculosis
clinical presentation, 422–423
organ system, 423
diagnosis of
differential, 427
histopathologic examination of
tissues, 426–427
imaging, 424–425
laboratory abnormalities, 423–424
PET scan, 427
epidemiology, 420
immunology, 422
microbiology
rapid testing, 426
smear and culture, 425–426
predisposing medical conditions
age, 420–421
underlying medical conditions, 421, 422
treatment
antituberculous chemotherapy, 427–428
corticosteroids, 428
prevention/infection control, 429
supportive therapy, 428
Mimics of (SBE/ABE), 237–238.See alsoInfective
endocarditis
Mimics, of abdominal infection, 268
Minimum inhibitory concentrations (MIC), 189,
493, 513, 523
Minocycline, 505
Mitral valve prolapse (MVP), 227
S. viridansand, 218
Modified smallpox, 477
Molluscum contagiosum,41
Monobactams, 537, 538
Monocytes, 341
Monotherapyvs.combination therapy
for VAP patient, 195
Moraxella catarrhalis, 164
MRI.SeeMagnetic resonance imaging (MRI)
MRSA.SeeMethicillin-resistantStaphylococcus
aureus(MRSA)
MS.SeeMultiple sclerosis (MS)
MSSA.SeeMethicillin-sensitiveStaphylococcus
aureus(MSSA); Methicillin-susceptible
Staphylococcus aureus(MSSA)
MSSA/MRSA
antimicrobial therapy of, 505–508
bacteremia/ABE, 503–504
clinical spectrum of, 503
CVC infections of, 504–505
diagnostic clinical pathway, 505
epidemiology of, 502
microbiology of, 501–502Index 571